Nav: Home

Investigational malaria vaccine shows considerable protection in adults in malaria season

February 15, 2017

An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria--the deadliest form of the disease--for the duration of the malaria season, according to new findings published in the February 15th issue of the journal Lancet Infectious Diseases. The study participants live in Mali, Africa, where they are naturally exposed to the parasite.

The investigational vaccine, known as the PfSPZ Vaccine, contains live but weakened sporozoites, the form of the parasite that infects humans, and was developed by scientists at Sanaria Inc., of Rockville, Maryland. The study was conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the University of Science, Techniques, and Technologies of Bamako (USTTB), Mali, one of NIAID's International Centers of Excellence in Malaria Research.

In 2015, 212 million cases of malaria occurred worldwide, and 429,000 people with malaria died, largely African children under five years old, according to the World Health Organization. Although only 1,500 to 2,000 cases of malaria are diagnosed in the United States each year, the disease is a concern for international travelers, aid workers and military personnel worldwide.

"Considerable progress has been made in the global fight against malaria within the past decade, yet far too many people--particularly young African children--continue to become infected and die from the disease," said NIAID Director Anthony S. Fauci, M.D. "A safe, effective vaccine to protect against this mosquito-borne illness would greatly help efforts to bring the disease under control."

Humans acquire malaria through the bite of infected mosquitoes, which inject parasites in the sporozoite stage of their life cycle into the bloodstream. The parasites travel to the liver, multiply, and then spread throughout the bloodstream causing malaria symptoms, including chills, fever, headache, nausea, sweating and fatigue.

PfSPZ Vaccine uses live but weakened sporozoites of the malaria parasite species P. falciparum to generate an immune response to protect against malaria infection. Earlier research found that the experimental vaccine safe and protective against malaria infection for up to a year in healthy U.S. adults who had not been previously exposed to malaria.

The Mali study was launched in January 2014 to provide additional safety data about PfSPZ Vaccine and determine if it could protect adults living in a malaria-endemic area against naturally occurring malaria infection. The study enrolled 109 healthy African men and non-pregnant women ages 18 to 35 years old. It was led by co-principal investigators Sara Healy, M.D., M.P.H., of NIAID's Laboratory of Malaria Immunology and Vaccinology, and Mahamadou Sissoko, M.D., M.P.H., of USTTB's Malaria Research and Training Center.

Participants received either five doses of the intravenous PfSPZ Vaccine or five doses of placebo (saline) over five months of the dry season at the study's clinical site in the Donéguébougou village in rural Mali. Clinical staff then actively monitored the participants during the six-month rainy, malaria-transmission season for the presence of malaria parasites in the blood.

The investigators report that the vaccine candidate was well-tolerated and safe with no serious adverse events. Among the 40 participants who received five placebo doses, 93 percent (37 participants) developed P. falciparum malaria infections; by comparison, 66 percent (27 participants) of the participants who received five doses of the PfSPZ Vaccine (41 participants) developed malaria infection. Based on the primary study analysis, PfSPZ Vaccine demonstrated a 48 percent protective efficacy by time-to-first positive malaria blood smear and 29 percent efficacy by proportion of participants with at least one positive malaria blood smear during a full 20-week malaria transmission season. By both measures of protective efficacy, there was statistically significant protection in the vaccine group as compared with the placebo group.

"This level of sustained efficacy against malaria infection in a region with an intense transmission season has not been seen in previous malaria vaccine studies in Africa," said Dr. Healy. "It is a very encouraging finding that we can, hopefully, build upon."

The vaccine-induced antibody response was considerably lower in the Mali study, however, than in the U.S. trial even though study participants received the same vaccine regimen.

"The poor antibody response to PfSPZ Vaccine among Malians could have been because of the participants' lifelong exposure to P. falciparum," said Patrick E. Duffy, M.D., chief of NIAID's Laboratory of Malaria Immunology and Vaccinology.

The investigators report that the intravenous delivery system for the PfSPZ Vaccine did not pose a problem to administer in a rural, malaria-endemic area--an initial concern about the experimental vaccine's unique design.

"Direct venous inoculation is not currently used for any licensed vaccines to prevent an infectious disease," said Professor Ogobara Doumbo, M.D., Ph.D., senior scientist for the Mali malaria vaccine program and chair of the Department of Epidemiology of Parasitic Diseases at USTTB. "In this study, we administered 491inoculations in a rural setting without a problem, and the dosages were delivered in a matter of seconds. It shows that this approach is feasible from both a logistical and public health standpoint."

According to the researchers, a preventive malaria vaccine employed in mass vaccination programs to eliminate P. falciparum from geographically defined areas would need to prevent malaria infection or transmission in at least 80 percent of recipients throughout the malaria transmission season. Clinical trials now underway in Africa, Europe and the United States have been designed to boost PfSPZ Vaccine's efficacy by increasing dosage levels and varying the timing and number of doses. The experimental vaccine is also being examined in demographic groups other than healthy adults, including adolescents, children and infants.
-end-
Sanaria was the regulatory sponsor of the trial; NIAID supported the development of the vaccine through the Small Business Innovation Research award 5R44AI055229.

Additional information about the PfSPZ Vaccine trial in Mali is available at ClinicalTrials.gov using the identifier NCT01988636. A follow-up study examining a three-dose PfSPZ Vaccine regimen with higher dosage levels has just been completed by the same clinical team in Mali, Africa. Results from that study will be available in mid-2017. Additional information about that research is also available at ClinicalTrials.gov using the identifier NCT02627456.

Reference: MS Sissoko et al. Safety and efficacy of PfSPZ vaccine against Plasmoidum falciparum via direct venous inoculation in healthy malaria-exposed Malian adults: a randomized, double-blind trial. The Lancet Infectious Diseases DOI: 10.1016/S1473-3099(17)30104-4 (2017).

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov. NIH...Turning Discovery Into Health®

NIH/National Institute of Allergy and Infectious Diseases

Related Malaria Articles:

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the Umeå University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.
Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.
New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.
Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.
Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.
Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.
Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.
The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.
Free malaria tests coupled with diagnosis-dependent vouchers for over-the-counter malaria treatment
Coupling free diagnostic tests for malaria with discounts on artemisinin combination therapy (ACT) when malaria is diagnosed can improve the rational use of ACTs and boost testing rates, according to a cluster-randomized trial published this week in PLOS Medicine by Wendy Prudhomme O'Meara of Duke University, USA, and colleagues.
More Malaria News and Malaria Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#568 Poker Face Psychology
Anyone who's seen pop culture depictions of poker might think statistics and math is the only way to get ahead. But no, there's psychology too. Author Maria Konnikova took her Ph.D. in psychology to the poker table, and turned out to be good. So good, she went pro in poker, and learned all about her own biases on the way. We're talking about her new book "The Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win".
Now Playing: Radiolab

Uncounted
First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at Radiolab.org/donate.